FGF23 and neoplasm: The pan-selective FGFR inhibitor NVP-BGJ398 dose-dependently blocked the response to 10ng/ml FGF23 (Figure 5B), from which we chose 25 or 40nM (14 or 22ng/ml) to test against growth of MM cells stably secreting Gaussia luciferase [21] to follow tumor burden [22].